Automated High Content Screening Microscopy

High Content Screening: Science, Techniques and Applications

Volumn , Issue , 2007, Pages 25-42

  Johnston, Paul A ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Automated high content screening microscopy; Automated imaging platforms; SAPK activation HCS assay

Indexed keywords

EID: 84889321021     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470229866.ch2     Document Type: Chapter

References (25)

1. Wang Y-l, Taylor DL, editors. Fluorescence microscopy of living cells in culture: Part A. Fluorescent analogs, labelling cells, and basic microscopy. Volume 29, Methods in cell biology. San Diego, California: Academic Press; 1989.
2. Taylor DL, Wang Y-l, editors. Fluorescence microscopy of living cells in culture. Part B, Quantitative fluorescence microscopy-imaging and spectroscopy. Volume. 30, Methods in cell biology. San Diego, California: Academic Press; 1989.
3. Giuliano KA, DeBiasio RL, Dunlay RT, Gough A, Volosky JM, Zock J, Pavlaki GN, Taylor DL. High-content screening: a new approach to easing key bottlenecks in the drug discovery process. Journal of Biomolecular Screening 1997;2:249-259.
4. Almhol DL, Loechel F, Nielse SJ, Krog-Jensen C, Terry R, Bjorn SP, Pedersen HC Praestegaard M, Moller S, Heide M, Pagliaro L, Mason AJ, Butcher S, Dahl SW. Nuclear export inhibitors and kinase inhibitors identified using a MAPK-activated protein kinase 2 redistribution screen. Assay and Drug Development Technologies 2004; 2:7-20.
5. Oakley RH, Hudson CC, Cruickshank RD, Meyers DM, Payne RE Jr, Rhem SM, Loomis CR. The cellular distribution of fluorescently labeled arrestins provides a robust, sensitive, and universal assay for screening G protein-coupled receptors. Assay and Drug Development Technologies 2002;1:21-30.
6. Trask OJ Jr, Baker A,William RG, Nickischer D, Kandasamy R, Laethem C, Johnston PA. Assay development and case history of a 32K-biased library high-content MK2-EGFP translocation screen to identify p38 mitogen-activated protein kinase inhibitors on the ArrayScan 3.1 imaging platform. Methods in Enzymology 2006;414:419-439.
7. Nickischer D, Laethem C, Trask OJ Jr, Williams RG, Kandasamy R, Johnston PA. Development and implementation of three mitogen-activated protein kinase (MAPK) signaling pathway imaging assays to provide MAPK module selectivity profiling for kinase inhibitors: MK2-EGFP translocation, c-Jun, and ERK activation. Methods in Enzymology 2006;414:389-418.
8. Moffat J, Grueneberg DA, Yang X, Kim SY, Kloepfer AM, Hinkle G, Piqani B, Eisenhaure TM, Luo B, Grenier JK, Carpenter AE, Foo SY, Stewart SA, Stockwell BR, Hacohen N, Hahn WC, Lander ES, Sabatin DM, Root DE. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 2006; 124:1283-1298.
9. Mayer TU, Kapoor TM, Haggart SJ, King RW, Schreiber SL, Mitchison TJ. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science 1999;286:971-974.
10. Mitchison TJ. Small-molecule screening and profiling by using automated microscopy. Chembiochem 2005;6:33-39.
11. Giuliano KA, Cheung WS, Curran DP, Day BW, Day BW, Kassick AJ, Lazo JS, Nelson SG, Shin Y, Taylor DL. Systems cell biology knowledge created from high content screening. Assay and Drug Development Technologies 2005;3:501-514.
12. Giuliano KA, Johnston PA, Gough A, Taylor DL. Systems cell biology based on highcontent screening. Methods in Enzymology 2006;414:601-619.
13. DeBiasio R, Bright GR, Ernst LA,Waggoner AS, Taylor DL. Five-parameter fluorescence imaging: wound healing of living Swiss 3T3 cells. Journal of Cell Biology 1987;105:1613-1622.
14. Gough AH, Johnston PA. Requirements, features, and performance of high content screening platforms. Methods in Molecular Biology 2007;356:41-61.
15. Lee S, Howell BJ. High-content screening: emerging hardware and software technologies. Methods in Enzymology 2006;414:468-483.
16. Pepperkok R, Ellenberg J, High-throughput fluorescence microscopy for systems biology. Nature Reviews Molecular Cell Biology 2006;7:690-696.
17. Berlage T. Analyzing and mining image databases. Drug Discovery Today 2005; 10:795-802.
18. Cowan KJ, Storey KB. Mitogen-activated protein kinases: new signaling pathways functioning in cellular responses to environmental stress. Journal of Experimental Biology 2003;206:1107-1115.
19. Garrington TP, Johnson GL. Organization and regulation of mitogen activated protein kinase signaling pathways. Current Opinion in Cell Biology 1999;11:211-218.
20. English JM, Cobb MH. Pharmacological inhibitors of MAPK pathways. Trends in Pharmacological Sciences 2002;23:40-45.
21. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK and p38 protein kinases. Science 2002;298:1911-1912.
22. Ono K, Han J. The p38 signal transduction pathway, activation and function. Cellular Signalling 2000;12:1-13.
23. Noble MEM, Endicott JA, Johnson LN. Protein Kinase Inhibitors: insights into drug design and structure. Science 2004;303:1800-1805.
24. Regan J, Breitfelder S, Cirillo P, Gilmore T, Graha AG, Hickey E, Klaus B, Madwed J, Moriak M, Moss N, Pargellis C, Pav S, Proto A, Swinamer A, Tong L, Torcellini C. Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate. Journal of Medicinal Chemistry 2002;45:2994-3008.
25. Fabbro D, Ruetz S, Buchdunger E, Cowan-Jacob SW, Fendrich G, Liebetanz J, Mestan J, O'Reilly T, Traxler P, Chaudhuri B, Fretz H, Zimmermann J, Meyer T, Carvatti G, Furet P, Manley PW. Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. Pharmacology and Therapeutics 2002;93:79-98.